Medical Policy and Coding Updates - September 2022
Summary
Effective December 1, 2022, botulinum toxin codes J0585, J0586, J0587 and J0588 require medical necessity review and prior authorization for dates of service starting on that date, and the new Botulinum Toxins policy (5.01.512) covers the listed indications. Krystexxa (pegloticase) must be given with oral methotrexate 15 mg weekly, unless there is a medical reason why methotrexate can't be taken. Effective September 1, 2022, codes J0591, 17107 and 17108 require review for cosmetic and prior authorization, and Dupixent (dupilumab) age criteria for atopic dermatitis changed from 6 years to 6 months of age and older.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.